Enopace Biomedical Ltd.
Enopace Biomedical Ltd. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Enopace Biomedical Ltd..
Enopace Biomedical Ltd. is a company.
Key people at Enopace Biomedical Ltd..
Key people at Enopace Biomedical Ltd..
Enopace Biomedical Ltd. is a medical technology company developing minimally invasive, implantable endovascular neuromodulation therapies for heart failure patients.[1][2][3][4][5] Its core product is a "stent-like" device that delivers electrical stimulation to the aorta's inner wall, paired with external units for powering, wireless communication, and personalized therapy adjustments, aiming to increase cardiac efficiency by reducing left ventricular workload.[2][3] The company serves the 20+ million heart failure patients in Europe and the US, addressing a major unmet need in cardiovascular care with high healthcare costs.[2] Growth momentum includes winning the 2017 #1 Medical Innovation award at the TCT Congress, leadership changes like David M. Handler becoming President and CEO in March 2023, and ongoing development from its base in Caesarea, Israel.[2][3]
Enopace Biomedical was founded by Rainbow Medical, an Israeli investment group focused on game-changing medtech solutions for large unmet needs.[2] The idea emerged to tackle congestive heart failure (CHF) through endovascular neuromodulation, a novel approach to reduce heart workload and boost efficiency.[1][2] Early traction came in 2017 when Enopace was voted #1 Medical Innovation by cardiologists at the Transcatheter Interventional Therapeutics (TCT) Congress, validating its technology after a rigorous review.[2] Leadership evolved with Amir Dagan as early CEO and Efi Cohen Arazi of Rainbow Medical providing backing; in 2023, David M. Handler joined as President and CEO, bringing experience from Philips Healthcare and Corindus Vascular Robotics, where he scaled robotics from prototype to FDA clearance and a $1.1B acquisition.[3]
Enopace rides the neuromodulation wave in medtech, targeting heart failure—a leading cause of death with 20+ million patients and massive costs—amid rising demand for device-based therapies over pharmaceuticals.[1][2] Timing aligns with advances in minimally invasive cardiology, endovascular tech, and personalized medicine, fueled by aging populations and post-pandemic focus on chronic conditions.[3] Market forces like FDA clearances for similar robotics (e.g., Handler's prior work) and investor interest in Israeli medtech hubs favor Enopace, positioning it to influence CHF treatment paradigms by pioneering aorta-targeted stimulation.[2][3]
Enopace is poised for clinical trials, FDA pathways, and partnerships, leveraging Handler's commercialization prowess to advance from prototype to market.[3] Trends like AI-integrated neuromodulation, wireless implants, and value-based care will shape its path, potentially expanding to related cardiovascular unmet needs.[2][3] Its influence may grow by setting standards in personalized heart failure therapy, validating Rainbow Medical's model and boosting Israel's medtech ecosystem—echoing its founding promise to not just extend life, but enhance how it's lived.[3]
